Relay Therapeutics Inc (RLAY) recent activity suggests a positive outlook with the last week’s performance of -10.33%

A new trading day began on Monday, with Relay Therapeutics Inc (NASDAQ: RLAY) stock price up 4.33% from the previous day of trading, before settling in for the closing price of $4.16. RLAY’s price has ranged from $4.11 to $12.14 over the past 52 weeks.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

Annual sales at Healthcare sector company grew by 319.82% over the past five years. Meanwhile, its annual earnings per share averaged 9.80%. With a float of $123.36 million, this company’s outstanding shares have now reached $166.89 million.

Let’s look at the performance matrix of the company that is accounted for 323 employees. In terms of profitability, gross margin is 58.64%, operating margin of -3926.55%, and the pretax margin is -3449.92%.

Relay Therapeutics Inc (RLAY) Insider and Institutional Ownership

As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Relay Therapeutics Inc is 26.30%, while institutional ownership is 73.16%. The most recent insider transaction that took place on Dec 16 ’24, was worth 500,000. In this transaction President and CEO of this company sold 100,000 shares at a rate of $5.00, taking the stock ownership to the 574,548 shares. Before that another transaction happened on Dec 16 ’24, when Company’s Officer proposed sale 100,000 for $5.00, making the entire transaction worth $500,000.

Relay Therapeutics Inc (RLAY) Latest Financial update

Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.61 per share during the current fiscal year.

According to the Wall Street analysts, stocks earnings will be around 9.80% per share during the next fiscal year.

Relay Therapeutics Inc (NASDAQ: RLAY) Trading Performance Indicators

Here are Relay Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 18.42. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 72.57.

For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.61, a number that is poised to hit -0.57 in the next quarter and is forecasted to reach -2.64 in one year’s time.

Technical Analysis of Relay Therapeutics Inc (RLAY)

Relay Therapeutics Inc (NASDAQ: RLAY) saw its 5-day average volume 2.85 million, a positive change from its year-to-date volume of 1.57 million. As of the previous 9 days, the stock’s Stochastic %D was 13.52%. Additionally, its Average True Range was 0.32.

During the past 100 days, Relay Therapeutics Inc’s (RLAY) raw stochastic average was set at 3.48%, which indicates a significant decrease from 21.70% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 83.77% in the past 14 days, which was lower than the 93.51% volatility it showed in the past 100 days.

At the time of writing, stock’s 50-day Moving Average is $5.37, while its 200-day Moving Average is $6.75. Nevertheless, the first resistance level for the watch stands at $4.43 in the near term. At $4.52, the stock is likely to face the second major resistance level. The third major resistance level sits at $4.67. If the price goes on to break the first support level at $4.18, it is likely to go to the next support level at $4.03. The third support level lies at $3.94 if the price breaches the second support level.

Relay Therapeutics Inc (NASDAQ: RLAY) Key Stats

With a market capitalization of 726.44 million, the company has a total of 167,383K Shares Outstanding. Currently, annual sales are 25,550 K while annual income is -341,970 K. The company’s previous quarter sales were 0 K while its latest quarter income was -92,210 K.